Real‐world patient characteristics, treatment patterns, and treatment outcomes of patients with diffuse large B‐cell lymphoma by line of therapy

Real‐world patient characteristics, treatment patterns, and treatment outcomes of patients with diffuse large B‐cell lymphoma by line of therapy

Abstract Background Although initial treatment of diffuse large B‐cell lymphoma (DLBCL) with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R‐CHOP) can be effective, up to 50% of patients will develop refractory or relapsed (R/R) disease. This study aimed to provide contempor...

Full description

Bibliographic Details
Main Authors: Helmneh M. Sineshaw, Christina M. Zettler, Jennifer Prescott, Mahek Garg, Samhita Chakraborty, Eric M. Sarpong, Claire Bai, Andrew J. Belli, Laura L. Fernandes, Ching‐Kun Wang
Format: Article
Language:English
Published: Wiley 2024-04-01
Series:Cancer Medicine
Subjects:
DLBCL
outcomes
relapsed/refractory
survival
treatment
Online Access:https://doi.org/10.1002/cam4.7173

Internet

https://doi.org/10.1002/cam4.7173

Similar Items